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Abstract
Anthrax is caused by infection with Bacillus anthracis, a spore-forming Gram-positive bacterium. A major virulence factor for
B. anthracis is an immunomodulatory tripartite exotoxin that has been reported to alter immune cell chemotaxis and
activation. It has been proposed that B. anthracis infections initiate through entry of spores into the regional draining lymph
nodes where they germinate, grow, and disseminate systemically via the efferent lymphatics. If this model holds true, it
would be predicted that surgical removal of infected tissues, debridement, would have little effect on the systemic
dissemination of bacteria. This model was tested through the development of a mouse debridement model. It was found
that removal of the site of subcutaneous infection in the ear increased the likelihood of survival and reduced the quantity of
spores in the draining cervical lymph nodes (cLN). At the time of debridement 12 hours post-injection measurable levels of
exotoxins were present in the ear, cLN, and serum, yet leukocytes within the cLN were activated; countering the concept
that exotoxins inhibit the early inflammatory response to promote bacterial growth. We conclude that the initial entry of
spores into the draining lymph node of cutaneous infections alone is not sufficient to cause systemic disease and that
debridement should be considered as an adjunct to antibiotic therapy.
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Introduction
The disease anthrax is caused by infection with Bacillus anthracis,
a Gram-positive bacterium whose dormant spores can infect most
warm-blooded hosts [1,2]. There are three different forms of
anthrax that are defined by the route by which spores are
introduced into the host: by inhalation, gastrointestinaly, and
cutaneously. Cutaneous infections account for ,95% of all human
cases and carry the lowest morbidity and mortality for anthrax
infections, resulting in 1% mortality upon treatment with
antibiotics and up to 20% mortality when untreated [3]. Eleven
of the twenty-two cases of anthrax associated with the intentional
release B. anthracis spores through the U.S. mail system in 2001
were cutaneous infections, demonstrating the propensity of this
bacterium to cause soft tissue infections [4].
Soft tissue debridement consists of surgically removing the
infected and/or necrotic tissue to promote healing and physically
eliminate the organisms infecting the tissue [5]. Debridement is
typically used, along with appropriate antibiotics, in the manage-
ment of necrotizing fasciitis, gangrene, and soft-tissue infections
caused by a wide range of organisms including Staphylococcus aureus,
Clostridium perfringens, and other pathogens that are refractory to
antibiotic treatment [6]. In these situations the infected tissues are
sacrificed to prevent the rest of the body from becoming
overwhelmed by the infection. Soft tissue infections by B. anthracis
demonstrate similarities to these infections, including extensive
tissue damage, necrotizing fasciitis, and having the potential to
cause lethal systemic infections [7]; thus debridement has been
examined as a means to reduce overall mortality [8,9,10]. The two
dominant views regarding its use for anthrax polarize around
whether surgery increases the risk of releasing bacteria into the
circulatory system versus removing the foci of infection to prevent
future spread of bacteria. Nonetheless, debridement was used as a
treatment for patients that injected B. anthracis-contaminated
heroin subcutaneously (‘‘popping’’) or intramuscularly [7,11].
We propose that the debate about when and if to apply
debridement to anthrax persists because the question has never
been addressed with a controlled experimental model in which one
experimental variable can be altered to assess cause and effect.
The goal of this study was to develop and substantiate an animal
model of debridement for anthrax to provide a broadly accessible
tool for the production of experimental evidence to guide the use
of debridement in the treatment of B. anthracis infections.
B. anthracis virulence is increased through the secretion of a
tripartite exotoxin and encapsulation with a poly-D-glutamic acid
capsule [12]. The tripartite exotoxin consists of protective antigen
(PA), lethal factor (LF), and edema factor (EF) [13]. PA in
combination with LF is referred to at lethal toxin (LT), and PA
combined with EF is referred to edema toxin (ET). When
considering the clinical implications of B. anthracis exotoxins, of
particular importance is the observation that, even with effective
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individuals demonstrating systemic signs of anthrax have a poor
prognosis [14]. This observation is often attributed to the lingering
effects of these exotoxins and must be considered when assessing
the timing and efficacy of debridement [2].
The most widely recognized model for B. anthracis dissemination
through the host is referred to as the Trojan horse model [15,16].
In this model, dormant spores are phagocytosed by resident
phagocytes and then transported to the draining lymph node
where they germinate and grow. Once the lymph node is
overwhelmed by bacterial growth, the bacteria then gain access
to the circulatory system via the efferent lymphatics. Most of the
data that support this model were produced with the aim of
deciphering the dynamics of inhalation anthrax. It is unclear how
much of this model applies to other versions of anthrax. Multiple
studies indicate that dissemination unfolds similarly after the
draining lymph nodes have been infected irrespective of the initial
site of infection [17,18]; implying that differences in the lethality
observed between cutaneous, gastrointestinal, or inhalation
anthrax are manifest upstream of the lymph nodes.
In the course of developing the debridement model in mice it
became apparent that the accumulating data had direct
implications on the application of the Trojan horse model to
subcutaneous infections. We hypothesized, based on the inhalation
Trojan horse model, that B. anthracis spores injected subcutane-
ously will quickly enter the draining lymph node and that the
spores that enter the lymph node early after inoculation are the
founding population of bacteria of the disseminated infection. This
hypothesis was tested by utilizing a luminescence-based mouse ear
model of subcutaneous anthrax coupled with debridement to
achieve delivery of a pulse of spores to the cervical lymph nodes
(cLN) draining the injection site. By removing the initial site of
inoculation the resultant infection is limited to those bacteria that
have entered the cLN during the time interval from injection to
excision of the injection site.
In this study we report that debridement of the site of
subcutaneous inoculation of B. anthracis spores in the mouse ear
up to 48 hours post-infection significantly increased the likelihood
of host survival. This observation questions the universality of the
Trojan horse dissemination model, which implies that the early
transit of B. anthracis into the lymph node is an essential step
towards systemic infection. In this subcutaneous model, the early
delivery of spores to the cLN was not sufficient to establish
disseminated infection. Instead bacterial growth at the initial site of
subcutaneous infection was necessary; an observation that does not
support the Trojan horse model in subcutaneous anthrax. We
propose that the initial site of cutaneous infection supplies bacteria
and exotoxins to the lymph node at a later time to cause the
disseminated infection. This mouse model of subcutaneous
infection experimentally demonstrated that debridement improves
the outcome of subcutaneous B. anthracis infections by limiting the
influence of bacteria within the initial site of infection and thus
should be further explored experimentally as an adjunct to
antibiotic therapy.
Results
Debate about the appropriate application of debridement to soft
tissue infections by B. anthracis has been hampered by lack of
experimental evidence to indicate or contraindicate its use. We
thus sought to develop a mouse model for debridement. To
achieve this goal spores from a B. anthracis Sterne strain that
produces light during vegetative growth within a host (BIG23)
were injected subcutaneously in the ear of C5-deficient A/J mice.
Infection of A/J mice with non-capsulated toxigenic B. anthracis
Sterne strain is a widely used animal model for anthrax that
recapitulates many characteristics of infections caused by encap-
sulated toxigenic B. anthracis strains such as the Ames strain
[19,20], yet poses less risk to researchers, and thus makes the
model described here broadly accessible to researchers without
BSL3 facilities. The ear was chosen as the anatomic site of
infection for our studies because the ear architecture allows
efficient debridement, its translucence permits greater sensitivity
when detecting bacterial growth by light emission, and has been
frequently used for modeling infectious diseases [18,21,22,23,24].
Bioluminescent B. anthracis strains were applied in order to
qualitatively identify the initial site of infection, determine whether
all infected tissues were removed during the debridement
procedure, and allow the assessment of the dissemination of
bacteria over time. Initial sites of infection were identified by
bacterial luminescence at 12, 24, 48, and 72 hours and debrided
by notching the ear to efficiently remove the initial site of infection
(Figure 1A); similar to general mouse husbandry ear tagging
procedures. Control infected mice had a section of ear removed
that did not contain the infection, or as a second control, no
portion of the ear was removed. Debridement at 12 hours
significantly protected mice from subcutaneous infection with
two different doses of spores (Figure 1B and 1C). All mice that
were inoculated with 1610
5 spores and debrided survived,
whereas 67% of the control groups succumbed to systemic
infections (Figure 1B). Similarly, in mice inoculated with 1610
6
spores (approximately 100 LD50s), 50% of the debrided mice
survived, while all mice from control groups succumbed to
systemic infections (Figure 1C). Debridement of the ear signifi-
cantly decreased mortality when performed at 12, 24, and
48 hours post-infection, but lost significance after 72 hours post-
infection (Figure 1D). We conclude that debridement significantly
protected mice from subcutaneous infection if performed within
48 hours of subcutaneous inoculation.
There are multiple mechanisms by which debridement could
promote survival, one of which is the prevention of bacterial
dissemination from the site of inoculation to the draining lymph
node. We thus questioned the timing of entry of B. anthracis into
the draining lymph node post-inoculation and if bacteria had
indeed entered the draining lymph nodes during the interval
between inoculation and debridement as is predicted by the
Trojan horse model of infection. Accordingly, at 1, 12 and
24 hours post-infection the cervical draining lymph nodes were
removed and bacterial colony-forming units (CFU) were measured
for both the total number of bacteria (spores+vegetative cells) by
plating without heat treatment or for spores-only by heating the
samples to 65uC for 20 minutes to kill all germinating spores and
vegetative bacteria, and then plating for CFU [25]. Independent of
the initial dose, approximately 3–4% of injected spores arrived in
the draining lymph nodes as early as one hour after injection
(Figure 2). The number of spores in the lymph node remained
constant, and no outgrowth occurred as late as 24 hours after
infection (Figure 2A). To test the effect of debridement on
subsequent bacterial loads, lymph nodes were removed at 24 and
72 hours from mice that underwent debridement at 12 hours or
non-debrided control mice. At 72 hours post-injection the CFU
had dropped significantly by over a log and as at earlier time
points, all CFU were comprised of spores (Figure 2B). With
debridement there were significantly fewer spores in the cLN at
24 hours post-infection (p=0.0144), and insignificantly fewer
spores at 72 hours post-infection (p=0.0066) (Figure 2B). These
findings were unaffected by the dose of spores administered,
however the magnitude of measured CFU was proportionally
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time were CFU isolated from the contralateral lymph nodes
draining the uninoculated right ear (data not shown). Similar cLN
CFU were observed in infections using spores from a B. anthracis
strain that had PA, LF, and EF production eliminated (TKO)
(Figure 2D), suggesting that the above findings are spore mediated
and not LT or ET dependent. In total these data suggest that at
the time of debridement at 12 hours post-inoculation spores can
be found in the draining lymph nodes and thus these spores are
typically not sufficient to cause systemic infections since debride-
ment effectively increased the likelihood of mouse survival.
The clinical difficulty of treating anthrax, even after the bacteria
have been effectively controlled with antibiotics, has been
attributed to residual exotoxin activity within the host. Likewise,
B. anthracis exotoxins have been reported to modulate chemotaxis
and activation of host innate immune cells [26,27,28,29]. We thus
questioned whether exotoxins were present at the time of
debridement, since they could be locally influencing the
chemotaxis of potential Trojan horse cells, altering the activation
state of innate immune defenses, or contributing to overall
mortality even after the bacteria were surgically removed. At
12 hours, the earliest time of debridement, 4586216 pg LF was
isolated from the ear, 28610 pg in the draining lymph node, and
476682 pg/ml in the serum of mice that received 1610
6 BIG23
spores subcutaneously (Table 1). When TKO spores were co-
inoculated with purified LT (100 ng LF+650 ng PA), the LF
distributed into the ear, lymph nodes, and serum similarly to the
LF actively produced by the exotoxin-producing BIG23; with
relatively equal proportions of the total LF distributed to the ear
and serum and approximately one-twentieth of the quantity found
in the cLN as in the ear and serum (Table 1). These LF
concentrations were assessed using a highly sensitive mass
Figure 1. Debridement significantly increases mouse survival from subcutaneous B. anthracis infection. (A) Black and white photos of a
single A/J mouse infected with 1610
5 BIG23 spores in the left ear overlaid with false-color representation of photon emission intensity as indicated
by the scale on the right in p/s/cm-2/sr. At 12 hours post injection luminescent infected tissue (left photo- before) was removed (debrided) to
eliminate all bacterial luminescence (right photo- after). (B to D) BIG23 spores were injected subcutaneously into the left ear of 4–12 week old A/J
mice. Control mice either had their left ear unperturbed (control) or non infected tissue on the same ear was removed (cut control). Mice were then
monitored for infection and dissemination using in vivo bioluminescent imaging. Mice were monitored for a total of ten days post-infection (p.i.),
until luminescence was detected in a major organ, or mouse appeared moribund (indicating imminent death). (B) Mice were inoculated with 1610
5
spores of BIG23. Luminescent tissue was debrided at 12 hours p.i. Survival data from a total of seven mice from three independent experiments were
analyzed with the log rank test to determine significant differences in survival between debrided and control mice (*, p=0.0108), and debrided and
cut control mice (**, p=0.0021). There was no statistical difference between control and cut control mice. (C) Mice were inoculated with 1610
6
spores of BIG23. Luminescent tissue was debrided at 12 hours p.i. Survival data was analyzed with the log rank test on a total of ten debrided mice
and seven mice each for the control groups from three independent experiments to determine significant differences in survival between debrided
and control mice (*, p=0.0109) and debrided and cut control mice (**, p=0.0026). There was no statistical difference between control and cut control
mice. (D) Mice were infected with BIG23 as described above, but debridement of luminescent tissue was performed at 24, 48, or 78 hour p.i. Survival
data was analyzed with the log rank test on a total of seven mice from each experimental group, with the exception of the control mice that totaled
six, from three independent experiments to determine significant differences from control mice. The survival of mice debrided at 24 hours
(*, p=0.0110) and 48 hours (*, p=0.0477) p.i. was significantly increased. The survival of mice debrided at 72 hours p.i. was not significantly different
than control mice (p=0.1734).
doi:10.1371/journal.pone.0030201.g001
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originally designed to assess LF concentrations in serum [30], but
was adapted here to study solid tissues. To date this is the most
sensitive assay for detecting any of the components of the B.
anthracis exotoxins and may reflect total exotoxin production since
the individual exotoxin components are coordinately regulated
[31]. Notably, the majority of debrided mice did not succumb to
infection, even with measurable circulating exotoxins, implying
that these concentrations of LF alone are not sufficient to mediate
death. Likewise when TKO spores were used to initiate infection,
a similar number of spores were found in the cLN as wild-type
Sterne strain bacteria during the same time period (Figure 2D).
This suggests that spore entry into the cLN is not affected by LT or
ET, counter to what may have been predicted based on published
cell culture analyses that demonstrated exotoxin-based alterations
in phagocyte activation and chemotaxis towards lymph nodes
[27,32,33,34,35].
Since exotoxins were present at the earliest time of debride-
ment, we next asked whether they had any measurable effect on
innate immune cell activation within the draining lymph nodes.
Accordingly, spores from B. anthracis Sterne or the TKO mutant
were injected subcutaneously into the left ear of mice at a
concentration of 1610
6 spores and at 24 hours cLN were
Figure 2. B. anthracis spores are found in the draining cervical lymph node early in infection. (A–C) BIG23 spores were inoculated
subcutaneously into the left ear of 4–12 week old A/J mice. At the indicated times cervical draining lymph nodes were removed and CFU derived
from vegetative cells verses spores were differentiated by quantifying samples with and without heat treatment (HT). Bars denote the mean and error
bars represent the standard error of the mean. Significance was determined using Student’s T-est. (A) Quantification of bacteria within the draining
lymph node at 1, 12, and 24 hours post-infection (p.i.) from mice inoculated with 1610
6 spores. There were no significant differences with or without
heat treatment or between different time points using a total of six mice in three independent experiments. (B) Quantification of bacteria within the
draining lymph node at 24 and 72 hours p.i. with and without debridement (DB) performed at 12 hours after inoculation with 1610
6 spores.
Significant differences were observed in a total of six mice in three independent experiments between 24 hr and 24 hr DB (*, p=0.0144) and 24 hr
and 72 hr (**, p=0.0066). There were no significant differences between heated and unheated samples at either time with or without debridement.
(C) Bacteria within the lymph node were quantified similarly to A at 1, 12, and 24 hours p.i., but with an inoculation of 1610
5 spores in a total of six
mice in three independent experiments. There were no significant differences with or without heat treatment. (D) Bacteria within the lymph nodes
were quantified similarly to A at 1 and 24 hours p.i., but instead, 1610
6 spores of the mutant strain that produced no exotoxins (TKO) were inoculated
in a total of six mice in three independent experiments. There were no significant differences with or without heat treatment.
doi:10.1371/journal.pone.0030201.g002
Table 1. Lethal Factor is measurable in the ear, draining
cervical lymph nodes and serum at the time of debridement
12 hours after spore inoculation.
Strain Ear
C cLN
CD Serum/ml
C
BIG23
A 4586216 28610 476682
TKO
B 15926681 49613 23546223
AInjection of 1610
6 luminescent 7702 (BIG23) spores subcutaneously into left
ear of 3 A/J mice.
BInjection of 1610
6 triple exotoxin knockout (TKO) spores with 100 ng LF plus
650 ng PA into left ear of 3 A/J mice.
CLF detected by anatomic locations (pg/tissue 6 SE) 12 hours post inoculation.
Average of three separate experiments with three mice.
DCervical lymph node.
doi:10.1371/journal.pone.0030201.t001
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Expression of the activation markers CD69, CD80 and CD86
were chosen as measures of activation since previous publications
have demonstrated that these cell markers are down regulated by
B. anthracis exotoxins [36,37,38]. Specifically, CD80 and CD86 are
down regulated in dendritic cells [37,39], and CD69 is down
regulated in response to LT in T cells at 24 hours [36]. Flow
cytometry revealed that expression of CD69 and CD86, but not
CD80, were significantly up-regulated in mice that had been
infected with Sterne or TKO spores as compared to internal
control lymph nodes (Figure 3A to C). The degree of up-regulation
was the same regardless of the ability of bacteria to produce
exotoxin. cLN analyzed at 12 hours post-infection demonstrated
no increase in CD69, CD80, or CD86 under any conditions (data
not shown). These findings suggest that exotoxins are not present
in the lymph node in sufficient quantities to alter cellular response
to inflammatory stimuli in the first 24 hours of B. anthracis
infection.
Discussion
Early events in B. anthracis infections are crucial in determining
the ultimate outcome of infection. Antibiotic treatment can
eliminate most vegetative bacteria growing in a host, yet frequently
the sequelae of infection exacerbated by lingering exotoxins still
lead to death [2]. It is therefore vital that the early events in B.
anthracis infections are better understood such that properly
conceived therapeutic interventions can be administered to
promote survival. The studies described above explored early
events in subcutaneous B. anthracis infections and support the
following major conclusions: 1) debridement can effectively reduce
the lethality of subcutaneous infections in a mouse model of
infection, and 2) early delivery of spores into the draining lymph
nodes during subcutaneous infections is not sufficient to cause
disseminated disease.
In addition to appropriate antimicrobial therapy, debridement
has been an effective method in the management of certain soft
tissue infections for over a century [5]. The data derived from the
mouse model of subcutaneous infection support the consideration
of debridement as therapy for some cases of subcutaneous anthrax,
since survival was significantly improved in mice debrided within
48 hours of infection; though it should be noted that debridement
at 72 hours post-infection trended towards greater protection as
well. These findings may have particular relevance to infections
initiated by subcutaneous introduction of illicit drugs, such as those
documented in Scotland in 2010 and Norway in 2000 [7,40]. To
our knowledge this is the first controlled experimental evidence to
support debridement in anthrax associated with soft tissues.
Although there are important caveats to using a mouse model of
infection, advantages offered by murine models of infection
include the availability of genetically manipulated mice, an
extensive array of immunological reagents, and the potential for
producing data of greater statistical strength granted by their high
reproduction rate and small body size. Subsequent corroboration
of that which was learned in mice to studies in non-human
primates or retrospective studies where debridement was applied
to human anthrax would ultimately be necessary to demonstrate
practical utility in human anthrax. Likewise, it should not be
overlooked that the model system applied in these studies utilizes a
BSL2 B. anthracis Sterne strain that does not produce capsule. The
lack of capsule production has been demonstrated to alter aspects
of pathogenesis in mouse models of infection [18,41]. Some strains
of capsulated exotoxin-producing B. anthracis do not require
exotoxins to maintain full virulence in subcutaneous infection,
such as the Ames strain [42], yet others such as UT500 do require
exotoxin production for full virulence [43]. Thus, it is unknown
how bacterial capsule production may affect the observations
reported here, but should be addressed by future research.
As proposed by the Trojan horse model of infection, spores that
enter the lymph nodes at the earliest stages of infection eventually
cause the disseminated infection [16]. This model would predict
that removal of the site of infection by debridement after spores
had entered the draining lymph nodes should have minimal effect
on the outcome of infection, since it is these spores that are most
important to establishing a lethal infection. This, however, was not
observed; instead, mice were more likely to survive with
debridement. A similar sequence of events would then unfold in
the lymph node, such that when its resistance thresholds are
overcome by bacteria and/or exotoxins, the bacteria and
exotoxins then spill into the lymphatics and blood to cause
bacteremia and/or toxemia leading to eventual death. Indeed, B.
anthracis exotoxins were detected at the site of infection, in the
circulatory system and in the draining lymph nodes at 12 hours
post-infection as described above. Thus debridement may improve
outcomes by simultaneously removing bacteria and eliminating
the source of exotoxins that disperse to tissues not containing
bacteria. That which defines the thresholds controlling the
infection locally has not been clearly defined, but likely includes
effector cells of the innate immune response; implying that the
immune status of the host is vital in defining the final outcome of
infection.
Considering the Trojan horse model, the improved survival
with debridement was unexpected, especially considering that the
primary inoculation dose would have been lethal otherwise.
However, the totality of results presented above for the cLN
provide evidence that supports a different mechanism of
dissemination in subcutaneous infections. Approximately 4% of
the spores that were inoculated subcutaneously could be isolated
from the draining cervical lymph node within 1 hour of infection.
The number of spores in the lymph node remained unchanged for
the first 24 hours and then decreased by more than a log by
72 hours. At no time were vegetative heat-sensitive bacteria
detected in the cLN during this time course. Spores are generally
considered resistant to immune cell killing until they germinate
[44], thus the constant number of spores detected over the first
24 hours in undebrided mice may represent either a static
population of spores or a dynamic balance achieved by the influx
of new spores countered by germination and rapid killing of
nascent vegetative bacteria. A significant decrease in spores was
detected in the cLN at 24 hours after debridement at 12 hours,
which supports the second scenario, where total spore counts
represent a balance between influx and destruction.
Another unexpected finding was that early exotoxin production
had no effect on the ability of spores to enter or persist in the
lymph nodes or activate immune cells. The Sterne strain and the
TKO mutant showed no significant differences in bacterial CFU
in the lymph nodes at any time point or in their activation of the
cells within the lymph nodes despite evidence for production of
exotoxins in the tissues by the Sterne strain at equivalent times
post-infection. Of particular relevance is that ET has been
proposed to promote the chemotaxis of phagocytes towards lymph
nodes [35,39,45] and that LT has been extensively characterized
for its ability to modulate the immune system [27,32,33]. For these
reasons, we predicted that a greater number of spores from an
exotoxin-producing strain would be found in the lymph nodes and
that there would be a less robust immune response characterized
by the expression of fewer activation markers by cells within the
lymph nodes. In the context of a subcutaneous infection, our data
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Sterne strain or TKO spores subcutaneously in the left ear. At 24 hours cLN were taken from mice including: Sterne infected mice (solid line non-
shaded) along with control non-infected contralateral lymph nodes from Sterne infected mice (solid line shaded), and TKO infected (dashed line non-
shaded) and control non-infected contralateral lymph nodes from TKO infected mice (dashed line shaded). cLN were homogenized and cells were
stained for flow cytometry. Flow plots were gated for single event live CD45 positive cells. (A) Left- a representative histogram comparing expression
of CD69 in draining cLN. Right- The mean fluorescence intensity of lymph nodes draining either Sterne (*, p=0.0464) or TKO (*, p=0.0256) infections
from seven mice was significantly higher than contralateral control lymph nodes as determined using Student’s T test. (B) Left- a representative
histogram comparing expression of CD86 in draining cLN. Right- The mean fluorescence intensity of lymph nodes draining either Sterne
(*, p=0.0119) or TKO (**, p=0.0063) infections from seven mice was significantly higher than contralateral control lymph nodes as determined using
Student’s T test. (C) A representative comparison of CD80 expression in draining cLN. The mean fluorescence intensity of lymph nodes draining either
Sterne or TKO infections from seven mice was not significantly higher than lymph nodes that were not.
doi:10.1371/journal.pone.0030201.g003
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measurable exotoxin was present at the time of debridement at
12 hours post-infection. The cause of this discrepancy is unclear
but may reflect the fact that the quantities and timing of the
addition of exotoxins in previously published systems may not
accurately represent those during an active infection in vivo.
Indeed, the concentrations of LF detected in the model described
above are orders of magnitude lower than those measured in the
serum of Rhesus macaques two to four days post-inhalation of
spores [30]. The serum of these monkeys contained LF in the
hundreds of nanogram per milliliter range, which is closer to the
concentration of LF typically used in cell culture assays assessing
the affects of LT on cellular functions. It thus may follow that the
reported effects of B. anthracis exotoxins on cells of the immune
system better represent phenomena in later stages of infection
rather than the early stages of infection that were explored in this
study. In total these data suggest that during the first day post-
inoculation the host response in the lymph nodes, 1) is not affected
by the presence or absence of the anthrax exotoxins as indicated
by the measures described above, and 2) is effective at eliminating
B. anthracis.
The observation that the lymph nodes are the site of
considerable host defense is not surprising in view of the fact that
they consist of a diverse collection of immune effector cells. It does
however provide some doubt that sufficient quantities of spores are
carried by Trojan horse phagocytes to the lymph node at the early
stages of infection to ultimately overwhelm the lymph node
defenses. All indications from this study are that the lymph node is
an effective bulwark against systemic infection unless the initial site
of infection continues to feed bacteria and/or spores and exotoxins
into the lymph node. Thus the early movement of spores into the
lymph nodes in subcutaneous infection, either by phagocyte
transport or as extracellular bacteria, is unlikely to have a
significant effect on the ultimate outcome of the infection.
In summary, this study describes the first animal model system
to experimentally assess debridement as a method of treating
subcutaneous anthrax. In addition, the debridement model was
readily applied to exploring basic aspects of subcutaneous B.
anthracis infection. In particular it was effective at assessing the
most common model explaining early stages of B. anthracis
infection, whereby spores are seeded into the draining lymph
node where they grow and eventually cause disseminated disease.
The data acquired from this analysis suggest that spores initially
entering the draining lymph nodes have less of an influence on the
ultimate disseminated disease than those spores that continue to
reside and grow at the initial site of inoculation.
Materials and Methods
Ethics Statement
All mouse husbandry and manipulation were performed
following protocols approved by the University of Virginia Animal
Care and Use Committee (protocol #3671) conforming to
AAALAC International accreditation guidelines. When at all
possible we have strived to replace the use of animals in our studies
with in vitro or non-invasive assays, reduce the number of animals
utilized, and refine our use of animals to minimize their suffering
and maximize the data extracted from each experiment.
Bacterial Strains and growth conditions
B. anthracis Sterne strain 7702 was obtained from BEI Resources
(Manassas, VA). The B. anthracis Sterne 7702 strain with deletion
of the pagA, lef, and cya genes (referred to in the text as the triple
exotoxin knockout or TKO) was graciously provided by Dr. Scott
Stibitz from the Center for Biologics Evaluation and Research,
Food and Drug Administration [46]. BIG23 was constructed by
integrating plasmid pIG6-19, a kind gift from Michele Mock at the
Pasteur Institute, into B. anthracis strain 7702 using previously
described conjugative methods [18]. The resultant BIG23
expressed the luxABCDE genes from Photorhabdus luminescens under
the control of the protective antigen promoter, therefore the
vegetative cells of this strain as luminescent when growing with the
host. Spores of each B. anthracis strains were generated on NBY
5 mg/ml erythromycin agar plates with subsequent purification on
an Omnipaque (GE Healthcare, Inc., NJ) gradient as previously
published [18].
Mouse infection
4–12 week old female A/J mice were obtained from Jackson
labs, or bred in specific pathogen-free conditions within vivaria at
UVA. Mice were anesthetized with 3% isofluorane (Piramal
Healthcare, Andhra Pradesh, India) mixed with oxygen using an
Isotec 5 vaporizer (Absolute Anesthesia, Piney River, VA). Purified
B. anthracis spores at a dose of 1610
6 or 1610
5 spores in 10 ml PBS
(Invitrogen, Carlsbad, CA) were injected subcutaneously in the left
ear using a 0.5 cc insulin syringe as previously published [18].
Lymph node isolation: At designated time points infected
mice were euthanized and lymph nodes were surgically removed
and placed in sterile PBS on ice. The left cervical lymph node from
the infected side of the mouse was harvested as the experimental
sample and the right lymph node was harvested as an internal
control. The location of the lymph node draining the subcutane-
ous compartment of the left ear was established by injecting India
ink in the same manner as the spore inoculum and then identifying
which lymph node turned black [47]. Only one cervical lymph
node turned black and subsequent analysis found CFU solely
within this lymph node. No other cervical lymph nodes turned
black or contained CFU at early stages of infection, suggesting that
only the lymph node that directly drains the subcutaneous
compartment was infected by B. anthracis and not other lymph
nodes or surrounding tissues.
Tissue CFU determination
Lymph nodes were isolated as previously described, immedi-
ately stored on ice, and dissociated by grinding between two glass
slides. Cells were lysed in distilled water for 15 minutes on ice.
Serial dilutions were performed in 16sterile PBS on ice. Samples
were plated onto BHI agar plates, and incubated at 37uC
overnight. Determination of dormant spores verses vegetative
bacilli was established by placing samples in a 65uC water bath for
twenty minutes to kill vegetative bacteria but leave dormant spores
unaffected.
Flow cytometry staining
Single cell suspensions of individual lymph nodes were
resuspended in 100 ml flow cytometry staining buffer (16PBS
3% FBS 0.05% Sodium Azide). Fc receptor-blocking antibody
(CD16/32, eBioscience San Diego, CA) was added and incubated
on ice for thirty minutes. Samples were centrifuged and
resuspended in 100 ml flow staining buffer. Antibodies against
specific cell surface markers were added, incubated for one hour
on ice, and then washed. Samples were then fixed overnight with
4% paraformaldehyde at 4uC. Antibodies used were: anti-Ly6C
FITC (RB6-8C5, BD Biosciences), anti-CD86 PE (PO3.1,
eBioscience San Diego, CA), anti-CD11b APC (M1/70,
eBioscience), anti-MHC II PacBlue (M5/114.15.2, eBiosciences),
anti-CD80 PE Cy5 (16-10A1, eBioscience), anti-CD69 PE Cy7
(H1.2F3, eBioscience), and anti-CD45 Alexa780 (30-F11,
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Dead Cell Stain kit (Invitrogen).
Infection monitoring and luminescent imaging
In order to monitor the progression of infections using
luminescent BIG23, mice were anesthetized using 3% isoflourane
mixed with oxygen from the XGI-8 gas anesthesia system supplied
with a Xenogen IVIS Spectrum. Images were acquired as
previously reported and analyzed using Living Image software
(version 2.50.1, Xenogen) [18]. Once any detectible luminescent
signal was detected in a vital organ, or a mouse appeared
moribund, mice were euthanized per animal use protocol and
scored as dead in the survival assays.
Measurement of Lethal Factor concentration in tissue
samples
Mice were infected with 1610
6 spores of BIG23 spores or TKO
spores with 100 ng LF (B. anthracis recombinant exotoxin, BEI
Resources)+650 ng PA (B. anthracis recombinant exotoxin, BEI
resources) subcutaneously in the left ear. At 12 hours ears,
draining cervical lymph nodes, and blood were removed from
infected mice and samples were placed on ice. Then 100 ml of cell
lysis cocktail consisting of 0.2% Triton X-100 (Promega),
0.56 mg/ml Pefablock (AppliChem. Darmstadt, Germany),
3.125 mg/ml 6-aminohexanoic acid (Spectrum chemical. Bruns-
wick, NJ), 0.3125 mg/ml Antipain (VWR. West Chester, PA), and
22 mg/ml of E64-D (Cayman Chemical. Ann Arbor, MI) in PBS
were added to samples. Samples were then homogenized using
kontes pellet pestles (Fisher Scientific. Waltham, MA). Samples
then sat on ice for 1 hour. Samples were then spun down and
supernatants were removed and stored at 280 C. Blood samples
were allowed to clot for 20 minutes then spun down to collect
serum, which was then stored at 280uC. Quantification of LF was
performed using matrix assisted laser desorption/ionization
(MALDI) time of flight (TOF) mass spectrometry (MS) to detect
peptide cleavage products generated by LF as previously described
[30].
Statistical Analysis
All statistical analysis and was performed using GraphPad Prism
software (version 5, GraphPad Software, San Diego, CA) with log
rank test for survival studies, and unpaired t-test for differential
CFU in draining lymph node.
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